Findings

What do systematic reviews say?

3,747 questions · 3,943 findings · 594 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 784 · 19.9%GRADE not reported 530 · 13.4%Very low 1,040 · 26.4%Low 981 · 24.9%Moderate 444 · 11.3%High 164 · 4.2%

Probenecid vs allopurinol

Tophus regression ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzbromarone vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Benzbromarone showed no clear difference in withdrawal due to adverse events compared with allopurinol (low certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 1.25 [0.28, 5.62]
2 studies · 91 participants
Low

Benzbromarone vs allopurinol

Total adverse events · people with chronic gout

Benzbromarone showed no clear difference in total adverse events compared with allopurinol (low certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 3 [0.64, 14.16]
1 study · 55 participants
Low

Benzbromarone vs allopurinol

Pain reduction ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzbromarone vs allopurinol

Function ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzbromarone vs allopurinol

Tophus regression ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzbromarone vs probenecid

Acute gout attacks · people with chronic gout

Benzbromarone showed no clear difference in acute gout attacks compared with probenecid (low certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 0.73 [0.09, 5.83]
2 studies · 129 participants
Low

Benzbromarone vs probenecid

Serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) · people with chronic gout

Benzbromarone probably leads to higher serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) compared with probenecid (moderate certainty).

1 finding from 1 review

Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
RR 1.43 [1.02, 2]
1 study · 62 participants
Moderate

Proton pump inhibitors (PPI) vs control

Number of participants with worsening scores in corporal atrophy · people with pre‐malignant lesions

Proton pump inhibitor showed no clear difference in number of participants with worsening scores in corporal atrophy compared with control (low certainty).

1 finding from 1 review

Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions 2014 · Cochrane Headline outcomes only
OR 1.5 [0.59, 3.8]
4 studies · 1070 participants
Low

Proton pump inhibitors (PPI) vs control

Number of participants with worsening scores in corporal intestinal metaplasia · people with pre‐malignant lesions

Proton pump inhibitor showed no clear difference in number of participants with worsening scores in corporal intestinal… compared with control (low certainty).

1 finding from 1 review

Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions 2014 · Cochrane Headline outcomes only
OR 1.46 [0.43, 5.03]
5 studies · 1408 participants
Low

Proton pump inhibitors (PPI) vs control

Increase in the number of participants with simple (diffuse) hyperplasia after treatment · people with pre‐malignant lesions

It is very uncertain whether proton pump inhibitor changes increase in the number of participants with simple (diffuse)… compared with control (very low certainty).

1 finding from 1 review

Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions 2014 · Cochrane Headline outcomes only
OR 5.01 [1.54, 16.26]
6 studies · 1705 participants
Very low

Proton pump inhibitors (PPI) vs control

Increase in the number of participants with linear/micronodular (focal) hyperplasia, comparing final biopsies with baseline biopsies · people with pre‐malignant lesions

Proton pump inhibitor may leads to higher increase in the number of participants with linear/micronodular… compared with control (low certainty).

1 finding from 1 review

Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions 2014 · Cochrane Headline outcomes only
OR 3.98 [1.31, 12.16]
6 studies · 1705 participants
Low

Intervention not reported

months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)

The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).

1 finding from 1 review

Colchicine for pericarditis 2014 · Cochrane Headline outcomes only
RR 0.41 [0.28, 0.61]
2 studies · 360 participants
Moderate

Intervention not reported

Symptom relief at 72 hours Patient reported

The intervention may leads to higher symptom relief at 72 hours Patient reported (low certainty).

1 finding from 1 review

Colchicine for pericarditis 2014 · Cochrane Headline outcomes only
RR 1.4 [1.26, 1.56]
4 studies · 564 participants
Low

Intervention not reported

Total adverse effects Patient reported

The intervention showed no clear difference in total adverse effects Patient reported (low certainty).

1 finding from 1 review

Colchicine for pericarditis 2014 · Cochrane Headline outcomes only
RR 1.26 [0.75, 2.12]
4 studies · 564 participants
Low

Intervention not reported

Adverse effects necessitating stop of therapy Patient reported

The intervention probably leads to higher adverse effects necessitating stop of therapy Patient reported (moderate certainty).

1 finding from 1 review

Colchicine for pericarditis 2014 · Cochrane Headline outcomes only
RR 1.87 [1.02, 3.41]
4 studies · 564 participants
Moderate

Intervention not reported

months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)

The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).

1 finding from 1 review

Colchicine for pericarditis 2014 · Cochrane Headline outcomes only
RR 0.28 [0.17, 0.47]
2 studies · 204 participants
Moderate

Intervention not reported

months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)

The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).

1 finding from 1 review

Colchicine for pericarditis 2014 · Cochrane Headline outcomes only
RR 0.36 [0.23, 0.56]
2 studies · 204 participants
Moderate

Intervention not reported

months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)

The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).

1 finding from 1 review

Colchicine for pericarditis 2014 · Cochrane Headline outcomes only
RR 0.38 [0.25, 0.58]
2 studies · 204 participants
Moderate

Intervention not reported

months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers)

The intervention probably leads to lower months Chest pain + (ECG changes +/‐ echocardiographic changes +/‐… (moderate certainty).

1 finding from 1 review

Colchicine for pericarditis 2014 · Cochrane Headline outcomes only
RR 0.36 [0.23, 0.58]
2 studies · 360 participants
Moderate